Abstract：Objective: To investigate the expression of insulin-like growth factor-I (IGF-I) and epidermal growth factor receptor (EGFR) in uterine tissues and their relationship with myoma recurrence. Methods: The clinical data of 125 patients with hysteromyoma who underwent myomectomy from January 2018 to December 2018 were analyzed retrospectively. The expression of IGF-I and EGFR in myoma, Paratumor and myometrium were detected by immunohistochemistry. After 1 year follow-up, the patients were divided into recurrence group (37 cases) and nonrecurrence group (88 cases). The expression of IGF-I and EGFR in three kinds of uterine tissues of the two groups were analyzed and compared. Results: The expression of IGF-I and EGFR in different uterine tissues was statistically significant (P<0.05). The expression of IGF-I and EGFR in myoma, Paratumor and myometrium of patients with recurrence was higher than that of patients without recurrence (P<0.05). Conclusion: The expression level of IGF-I and EGFR in the myoma of patients with uterine leiomyoma is higher than that in the adjacent tissue and myometrium, and the increased expression intensity of IGF-I and EGFR may be one of the potential factors for the recurrence of myoma.
颜红丽, 郑丽华, 白昌民, 邵美丽. IGF-I EGFR在子宫组织的表达及与肌瘤复发的关系[J]. 河北医学, 2021, 27(1): 116-120.
YAN Hongli, ZHENG Lihua, BBAI Changmin, et al. Expression of IGF-I and EGFR in Uterine Tissues and Their Relationship with Recurrence of Leiomyoma. HeBei Med, 2021, 27(1): 116-120.
[1] Nikpey P,Nazari T,Khalili S,et al.The role of epidermal growth factor receptor (EGFR) common gene mutations in Iranian women with uterine fibroids.[J].Eur Obstet Gynecol Reprod Biol,2018,229(10):103~107. [2] Kyriakopoulos K,Domali E,Stavrou S,et al.Recurrent benign leiomyomas after total abdominal hysterectomy. Rich or poor estrogenic environment may lead to their recurrence?[J].Int Surg Case Rep,2018,44(2):191~193. [3] Surov A,Meyer HJ,Hohn AK,et al.Metabolo-volumetric parameters of 18F-FDG-PET can predict expression of EGFR and HIF 1alpha in uterine cervical cancer.[J].Cancer Biomark,2019,24(1):135~140. [4] Islam MS,Ciavattini A,Petraglia F,et al.Extracellular matrix in uterine leiomyoma pathogenesis:a potential target for future therapeutics[J].Hum Reprod Update,2018,24(1):59~85. [5] 李晶,陈晓娟,孙华盛.米非司酮预处理对腹腔镜下子宫肌瘤剥除术患者ER、PR及Ki-67原位表达及肌瘤复发率的影响[J].医学临床研究,2017,34(5):946~949. [6] 薛勤梅,张晋峰.子宫内膜息肉中表皮生长因子受体胰岛素样生长因子1受体的表达分析[J].山西医药杂志,2018,47(8):871~872. [7] 张志磊,阿艳妮.IGF-I和IGF-Ⅱ在子宫肌瘤患者血清中的水平及其与肿瘤组织ER、PR表达的相关性分析[J].广西医科大学学报,2017,34(8):1174~1176. [8] 安欣,崔志利,魏娉,等.环状RNA ciRS-7和EGFR在子宫内膜癌组织中的表达水平[J].河北医学,2019,25(8):1321~1325. [9] 宋瑜.子宫肌瘤患者外周血中IGF-I和IGF-Ⅱ水平的变化及其与ER表达的相关性[J].实用癌症杂志,2018,33(6):892~894. [10] 邹晓岚,叶茸茸,王洋,等.胰岛素样生长因子-1及其受体在肿瘤中的研究进展[J].重庆医学,2018,47(18):2474~2476,2479. [11] 钮怡超,吴悦茜,朱一萍,等.子宫肌瘤旁组织表皮生长因子受体、血清MMP-9表达与子宫肌瘤术后复发的相关研究[J].检验医学与临床,2018,15(8):1132~1135,1139 [12] 赵欣,文亚南,吴聪哲,等.EGFR、VEGF、ER、PR在子宫平滑肌肿瘤中的表达及意义[J].解放军预防医学杂志,2019,37(1):55~57,62. [13] 陈霞,金玲玲,郭婉姣.子宫肌瘤剔除术后残留复发的相关危险因素分析[J].中国计划生育学杂志,2020,28(3):432~434,438.
2021, Vol. 27 
冀公网安备13080202000677号